Key facts
- ArsenalBio’s last known valuation is $1.9B.
- It has raised $630.8M; the latest was Later Stage VC ($325.0M) in Sep 2024.
- Notable investors include SoftBank Investment Advisers, Kleiner Perkins, University of California, ARCH Venture Partners, Emerson Collective — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for ArsenalBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ArsenalBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArsenalBio
Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies. The company offers a full-stack research and development engine that generates multifunctional T-cell medicines, enabled by the specific insertion of large synthetic deoxyribonucleic acid sequences, enabling clinicians with next-generation autologous T-cell therapies to defeat cancer.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 289
- Website
- arsenalbio.com/
- Ownership
- Privately Held (backing)
ArsenalBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArsenalBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArsenalBio in its N-PORT filings yet. We sweep new filings monthly.